Clinical Trials Directory

Trials / Completed

CompletedNCT05253521

The Role of South Asian vs European Origins on Circulating Regenerative Cell Exhaustion

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
Canadian Medical and Surgical Knowledge Translation Research Group · Academic / Other
Sex
All
Age
40 Years
Healthy volunteers
Not accepted

Summary

ORIGINS-RCE is an observational, cross-sectional, two-arm study aimed at determining if an individual's ethnic origin influences the number of blood vessel-forming stem cells in the bloodstream. Circulating progenitor cells will be enumerated and the distribution patterns of these cell types will be assessed to determine if these parameters differ between individuals of South Asian origin and European origin. Specifically, this study will evaluate if differential regenerative cell exhaustion (RCE) may account, at least in part, for the differences in cardiovascular risk reported between individuals of South Asian vs European origin.

Detailed description

Individuals of South Asian origins have been reported to be at higher risk of ischemic heart disease than those of European origins. While differential morphometries and culturally related behavioural habits are believed to account in part for the difference, there is growing evidence that cardiometabolic risk factors can accelerate pro-vascular progenitor cell depletion and dysfunction. The cumulative effects that aberrant regenerative cell exhaustion (RCE) have on vessel repair accordingly increases the risk of atherothrombotic events. ORIGINS-RCE is an observational, cross-sectional, two-arm study that will evaluate the progenitor cell profiles of peripheral blood samples from 120 individuals (60 of South Asian origins, 60 of European origins). The working hypothesis is that individuals of South Asian and European origins have innately different progenitor profiles that can be further altered by behavioural/cultural habits. The resultant differences in RCE capability will affect the balance between pro-inflammatory and vessel repair functions that in turn contribute to the contrasting cardiometabolic risks exhibited between the two study cohorts.

Conditions

Timeline

Start date
2022-01-08
Primary completion
2023-01-18
Completion
2023-01-18
First posted
2022-02-23
Last updated
2023-02-09

Locations

3 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT05253521. Inclusion in this directory is not an endorsement.